Heart failure in elderly: Progress in clinical evaluation and therapeutic approach

Journal of Geriatric Cardiology

Volumn 10, Issue 2, 2013, Pages 165-177

  Iacoviello, Massimo ^a   Antoncecchi, Valeria ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Diagnosis; Elderly patient; Heart failure; Prognosis; Therapy

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRONEDARONE; EPLERENONE; GALECTIN 3; IRBESARTAN; IVABRADINE; LOSARTAN; NEBIVOLOL; PERINDOPRIL; PLACEBO; SPIRONOLACTONE;

ACUTE HEART FAILURE; ADRENERGIC SYSTEM; AGING; ANEMIA; APPETITE; BODY MASS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CENTRAL VENOUS PRESSURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; DEATH; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DIURETIC THERAPY; DRUG EFFICACY; DYSPNEA; ECHOCARDIOGRAPHY; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; INFECTION; KIDNEY DISEASE; MORBIDITY; MORTALITY; NEOPLASM; PERIPHERAL EDEMA; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; SHORT PORTABLE MENTAL STATUS QUESTIONNAIRE; TACHYCARDIA; TISSUE DOPPLER IMAGING; WHEEZING;

EID: 84883309182     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1671-5411.2013.02.010     Document Type: Review

References (102)

1. McMurray JJ, Adamopoulos S, Anker SD et al ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-1146. (Pubitemid 47311002)
3. McMurray JJ, Petrie MC, Murdoch DR, et al. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998; 19: P9-P16.
4. Fang J, Mensah GA, Croft JB, et al. Heart failure related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008; 52: 428-434. (Pubitemid 352040814)
5. Butler J, Kalogeropoulos A. Worsening heart failure hospitalization epidemic we do not know how to prevent and we do not know how to treat! J Am Coll Cardiol 2008; 52: 435-437.
6. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112: 3958-3968. (Pubitemid 43739494)
7. Redfield MM, Jacobsen SJ, Burnett Jr. JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202. (Pubitemid 36068707)
8. Rich MW. Pharmacotherapy of heart failure in the elderly: adverse events. Heart Fail Rev 2012; 17: 589-595.
9. Abete P, Testa G, Della-Morte D, et al. Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev 2013; 18: 529-551.
10. Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344: 17-22. (Pubitemid 32064840)
11. Kaila K, Haykowsky MJ, Thompson RB, et al. Heart failure with preserved ejection fraction in the elderly: scope of the problem. Heart Fail Rev 2012; 17: 555-562.
12. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259. (Pubitemid 44079340)
13. Lam CS, Donal E, Kraigher-Krainer E, et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13: 18-28.
14. Barker WH, Mullooly JP, Getchell W. Changing Incidence And Survival For Heart Failure In A Well-Defined Older Population, 1970-1974 and 1990-1994. Circulation 2006; 113: 799-805.
15. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance Of Heart Failure With Preserved Systolic Function In Patients > or =65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001; 87: 413-419. (Pubitemid 32149998)
16. Orimo H, Ito H, Suzuki T, et al. Reviewing the definition of "elderly". Geriatr Gerontol Int 2006; 6: 149-158.
17. Alexander KP, Newby LK, Armstrong PW, et al. Acute Coronary Care in the Elderly, In collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115: 2549-2569.
18. Bhuiyan T, Maurer M. Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep 2011; 5: 440-449.
19. Lee DS, Gona P, Albano I, et al. A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail 2011; 4: 36-43.
20. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47: 76-84. (Pubitemid 43005168)
21. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population based study. Eur Heart J 2008; 29: 339-347. (Pubitemid 351197754)
22. Oudejans I, Mosterd A, Bloemen JA, et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail 2011; 13: 518-527.
23. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11: 130-139.
24. Heckman GA, Patterson CJ, Demers C, et al. Heart failure and cognitive impairment: challenges and opportunities. Clin Interv Aging 2007; 2: 209-218.
25. Huijts M, van Oostenbrugge RJ, Duits A, et al. Cognitive impairment in heart failure: results from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) randomized trial. Eur J Heart Fail. Published Online First: Feb 5, 2013. Doi: 10.1093/eurjhf/hft020.
26. Kindermann I, Fischer D, Karbach J, et al. Cognitive function in patients with decompensated heart failure: the Cognitive Impairment in Heart Failure (CogImpair-HF) study. Eur J Heart Fail 2012; 14: 404-413.
27. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-839.
28. Jensen J, Ma LP, Bjurman C, et al. Prognostic values of NTpro BNP/BNP ratio in comparison with NTpro BNP or BNP alone in elderly patients with chronic heart failure in a 2-year follow up. Int J Cardiol 2012; 155: 1-5.
29. Vaes B, Gruson D, Van Pottelbergh G, et al. The impact of confounders on the test performance of natriuretic peptides for cardiac dysfunction in subjects aged 80 and older. Peptides 2012; 38: 118-126.
30. Wang TJ, Larson MG, Levy D at al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90: 254-258. (Pubitemid 34804560)
31. Fradley MG, Larson MG, Cheng S, et al. Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 2011; 108: 1341-1345.
32. Costello-Boerrigter LC, Boerrigter G, Redfield MM et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 345-353. (Pubitemid 43063253)
33. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012; 60: 1249-1256. doi: 10.1016/j.jacc.2012.04.053.
34. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43: 60-68. doi: 10.3109/07853890.2010.538080.
35. Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012; 5: 72-78.
36. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-2550. (Pubitemid 47614269)
37. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165-193.
38. Benbarkat H, Addetia K, Eisenberg MJ, et al. Application of the Seattle heart failure model in patients >80 years of age enrolled in a tertiary care heart failure clinic. Am J Cardiol 2012; 110: 1663-1666.
39. Manzano L, Babalis D, Roughton M, et al SENIORS Investigators. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail 2011; 13: 528-536.
40. Eggers KM, Venge P, Lind L. Prognostic Usefulness of the Change in N-terminal pro B-type Natriuretic Peptide Levels to Predict Mortality in a Single Community Cohort Aged ≥ 70 Years. Am J Cardiol 2013; 111: 131-136.
41. Tsang TS, Barnes ME, Gersh BJ, et al. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol 2003; 42: 1199-1205. (Pubitemid 37188341)
42. Zile MR, Gottdiener JS, Hetzel SJ, et al.; I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011; 124: 2491-2501.
43. Murad K, Kitzman DW. Frailty and multiple comorbidities in the elderly patient with heart failure: implication for management. Heart Fail Rev 2012; 17: 581-588.
44. Pilotto A, Addante F, Franceschi M, et al. Multidimensional Prognostic Index based on a comprehensive geriatric assessment predicts short-term mortality in older patients with heart failure. Circ Heart Fail 2010; 3: 14-20.
45. Panella L, La Porta F, Caselli S, et al. Predicting the need for institutional care shortly after admission to rehabilitation: Rasch analysis and predictive validity of the BRASS Index. Eur J Phys Rehabil Med 2012; 48: 443-454.
46. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456.
47. Cohen-Solal A, McMurray JJ, Swedberg K, et al CHARM Investigators. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity programme. Eur Heart J 2008; 29: 3022-3028.
48. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587. (Pubitemid 30240502)
49. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717. (Pubitemid 29407370)
50. Zannad F, McMurray JJ, Krum H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
51. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543-551. (Pubitemid 39025171)
52. Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004; 148: 971-978. (Pubitemid 39646969)
53. Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357: 1229-1237.
54. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134: 550-560. (Pubitemid 32245316)
55. Flather MD, Shibata MC, Coats AJ, et al.; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225. (Pubitemid 40222359)
56. Düngen HD, Apostolovic S, Inkrot S, et al.; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CI-BIS-ELD trial. Eur J Heart Fail 2011; 13: 670-680.
57. Gelbrich G, Edelmann F, Inkrot S, et al; CIBIS-ELD investigators. Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly. Int J Cardiol 2012; 155: 160-166.
58. Reil JC, Custodis F, Swedberg K, et al. Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 2011; 100: 11-19.
59. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-974. (Pubitemid 40695027)
60. Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102: 11-22.
61. Reil JC, Reil GH, Böhm M. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction. Trends Cardiovasc Med 2009; 19: 152-157.
62. Custodis F, Baumhäkel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008; 117: 2377-2387. (Pubitemid 351653554)
63. Colin P, Ghaleh B, Monnet X, et al. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 2004: 308: 236-240. (Pubitemid 38090723)
64. Swedberg K, Komajda M, Böhm M, et al.; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885.
65. Borer JS, Böhm M, Ford I, et al.; SHIFT Investigators. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 2012; 33: 2813-2820.
66. Tardif JC, O'Meara E, Komajda M, et al.; SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32: 2507-2515.
67. Swedberg K, Komajda M, Böhm M, et al.; SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012; 59: 1938-1945.
68. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 2003; 107: 346-354. (Pubitemid 36135235)
69. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003; 107: 490-497. (Pubitemid 36158054)
70. Cleland JG, Tendera M, Adamus J, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail 1999; 1: 211-217. (Pubitemid 30129389)
71. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010; 55: 526-537.
72. Yusuf S, Pfeffer MA, Swedberg K, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781. (Pubitemid 37093918)
73. Massie BM, Carson PE, McMurray JJ, et al.; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
74. van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al., SENIORS Investigators. Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009; 53: 2150-2158.
75. Ghio S, Magrini G, Serio A, et al.; SENIORS investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006; 27: 562-568.
76. Bergström A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004; 6: 453-461. (Pubitemid 38746589)
77. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110: 558-565. (Pubitemid 39031173)
78. Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011; 162: 966-972.
79. Borlaug BA. Treatment of heart failure with preserved ejection fraction. Curr Treat Opt Cardiovasc Med 2009; 11: 79-87.
80. Mogensen UM, Ersbøll M, Andersen M, et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail 2011; 13: 1216-1223.
81. Persson H, Lonn E, Edner M, et al Investigators of the CHARM Echocardiographic Substudy-CHARMES. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 2007; 49: 687-694. (Pubitemid 46205045)
82. Bhuiyan T, maurer MS, Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep 2011; 5: 440-449.
83. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27: 178-186. (Pubitemid 43069034)
84. Neuberg GW, Miller AB, O'Connor CM, et al.; PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002; 144: 31-38. (Pubitemid 34734752)
85. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.
86. Iacoviello M, Puzzovivo A, Monitillo F, et al. Independent role of high central venous pressure in predicting worsening of renal function in chronic heart failure outpatients. Int J Cardiol 2013; 162: 261-263.
87. Zhou XJ, Rakheja D, Yu X, et al. The aging kidney. Kidney Int 2008; 74: 710-720.
88. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: "There's got to be a happy medium". JAMA 2010; 304: 1592-1601.
89. Camm AJ, Kirchhof P, Lip GY, et al European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-1420.
90. Schafer JA, Kjesbo NK, Gleason PP. Dronedarone: current evidence and future questions. Cardiovasc Ther 2010; 28: 38-47.
91. Haegeli LM, Duru F. Management of patients with atrial fibrillation: specific considerations for the old age. Cardiol Res Pract 2011; 854205.
92. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-1940. (Pubitemid 26428217)
93. Moss AJ, Zareba W, Hall WJ, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883. (Pubitemid 34984635)
94. Bardy GH, Lee KL, Mark DB, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237. (Pubitemid 40110811)
95. Huang DT, Sesselberg HW, McNitt S, et al.; MADIT-II Research Group. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol 2007; 18: 833-838. (Pubitemid 47093069)
96. Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med 2010; 153: 592-599.
97. Ghanbari H, Dalloul G, Hasan R, et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med 2009; 169: 1500-1506.
98. van Rees JB, Borleffs CJ, Thijssen J, et al. Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain. Europace 2012; 14: 66-73.
99. Revenco D, Morgan JP, Tsao L. The dilemma of implantable cardioverter-defibrillator therapy in the geriatric population. J Geriatr Cardiol 2011; 8: 195-200.
100. Padeletti L, Arnar DO, Boncinelli L, et al.; EuropeanHeart RhythmAssociation; Heart Rhythm Society. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010; 12: 1480-1489.
101. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007; 297: 2502-2514. (Pubitemid 46953404)
102. Verbrugge FH, Dupont M, De Vusser P, et al. Response to cardiac resynchronization therapy in elderly patients (>=70 years) and octogenarians. Eur J Heart Fail 2013; 15: 203-210.